Barinthus Biotherapeutics (BRNS) Return on Invested Capital (2021 - 2026)

Barinthus Biotherapeutics has reported Return on Invested Capital for 6 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Invested Capital changed 0.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (changed 0.0% YoY), and the FY2025 full-year result was 0.01%, changed 0.0% from the prior year.
• Return on Invested Capital for Q1 2026 stood at 0.01%, up from 0.01% in the prior quarter.
• The five-year high for Return on Invested Capital was 0.0% in Q3 2022, with the low at 0.01% in Q4 2025.
• Historically, Return on Invested Capital has averaged 0.0% across 5 years, with a median of 0.0% in 2023.
• The largest YoY upside for Return on Invested Capital was 0 bps in 2022 against a maximum downside of 0 bps in 2022.
• Barinthus Biotherapeutics' Return on Invested Capital stood at 0.0% in 2022, then tumbled by 313 bps to 0.0% in 2023, then slipped by 11 bps to 0.0% in 2024, then plunged by 89 bps to 0.01% in 2025, then advanced by 10 bps to 0.01% in 2026.
• The last three Return on Invested Capital figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.